AXIN2 and non-small cell lung carcinoma: Zhang et al. (Zhang et al. 2022) conducted targeted sequencing with the 1000-gene panel in NSCLC patients treated with EGFR TKIs and found that AXIN2 might be one of the key genes to the prognosis of NSCLC treated with EGFR TKIs.